Breakthrough for AlzeCure in the development of drugs for nerve pain

AlzeCure Pharma shows positive results from its clinical study with a new non-opioid drug candidate developed against peripheral neuropathic pain.

AlzeCure Pharma’s CEO Martin Jönsson.

New data from AlzeCure’s phase IIa study show that the drug candidate ACD440 has a significant analgesic effect on pain induced by cold and heat.

– The medical need in this area is immense, not least to find alternatives to opioids. Neuropathic pain is the single largest market segment in pain management, generating over $11 billion in annual revenues. Up to 80 percent of all patients do not get a satisfactory effect with their current treatments, said AlzeCure Pharma’s CEO Martin Jönsson.

AlzeCure is among a handful of companies in the world that develop drugs that target the TRPV1 receptor, whose discovery was awarded the 2021 Nobel Prize in Medicine. The goal is to help people who suffer from nerve pain. In many cases today, there is no other effective treatment available than opioids, which both numb the whole body and can lead to addiction and substance abuse.

More on the new study.

Welcome to The Park Novum!

At The Park Novum, you’re met with spacious offices, creative spaces, and a sweeping view over a growing Flemingsberg. Here, entrepreneurs, innovators, and researchers can find a home that not only provides a modern workplace, but also the opportunity to grow together.

DreamHack 2025: When Visibility Becomes a Strategic Asset for Early-Stage Game Studios

DreamHack Stockholm is not just a festival. It is one of the few occasions in Sweden where audiences, creators, and the industry move within the same space at the same time. In 2025, DreamHack set a new attendance record with over 60,000 visitors at Stockholmsmässan in Älvsjö, with attendees coming from 70 countries. This year, Press Start Game Hub, the game initiative based in Flemingsberg, took part.

2023-06-22T12:22:38+02:00
Go to Top